1 (Lenalidomide Capsules 1)
Lenalidomide Capsule
Product Images NDC 60219-1715
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 60219-1715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
8 (Lenalidomide Capsules 10)
9 (Lenalidomide Capsules 11)
This text appears to be a medication guide for Lenalidomide Capsules, warning about the potential risk of human birth defects. It also includes details like NDC code and dosage information. The document seems to be accessible at documents.amneal.com/mg/lenalidomide-caps.*
10 (Lenalidomide Capsules 12)
This is a Medication Guide for Lenalidom Capsules, NDC 60219-1718. It includes important information such as dosages, composition, and precautions. The guide emphasizes potential risks, including the possibility of birth defects. To access the full guide, visit the provided link or scan the QR code.*
11 (Lenalidomide Capsules 13)
The text appears to be a medication guide or information related to Lenalidomide capsules. It includes a QR code, NDC number 60219-1719, and dosage instructions. Additionally, it contains a warning about the potential for human birth defects associated with the medication.*
2 (Lenalidomide Capsules 2)
3 (Lenalidomide Capsules 3)
Survival probabilities and overall survival rates are being evaluated in a study involving a certain number of subjects. The survival probability at 100% is visible along with details about survivors in different categories. The data includes percentages for different groups, and further analysis on the survival rates is likely provided in the complete text.*
01 (Lenalidomide Capsules 4)
This text provides information on the comparison between Lenalidomide and placebo in terms of Progression-free Survival. It includes statistics such as Hazard Ratio (HR), Confidence Interval (CI), KM median, and the number of subjects at risk for the study. The data shows the percentage of PFS events for both Lenalidomide and placebo groups, indicating that Lenalidomide had 97 events out of 231 subjects (42%), while placebo had 116 events out of 229 subjects (51%).*
02 (Lenalidomide Capsules 5)
This text provides survival probability data for lenalidomide and placebo treatments, indicating hazard ratio, confidence intervals, and number of subjects at risk for progression-free survival events. The table includes percentages, confidence intervals, and the number of subjects for each treatment group.*
4 (Lenalidomide Capsules 6)
This text provides information about the proportion of subjects in a study, along with survival statistics such as Hazard Ratio and Log Rank p-value. It mentions Lenaldonide Capsules and Dexamethasone. Additionally, there is a graph showing Time to Progression in months for different groups.*
5 (Lenalidomide Capsules 7)
This text seems to be showing statistical results from a medical research study comparing the effectiveness of Lenalidomide Capsules/Dexamethasone versus Placebo/Dexamethasone in terms of Time to Progression in months. It provides hazard ratio (HR) with a 95% confidence interval, log rank test result (p-value <0.001), and the number of participants in each group. The findings suggest a statistically significant difference in Time to Progression between the two treatments.*
5 (Lenalidomide Capsules 8)
7 (Lenalidomide Capsules 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
